| REVIEW ARTICLE |
|
| Year : 2009 | Volume
: 5
| Issue : 9 | Page : 36-40 |
|
|
Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors
Jean-Francois Chatal, Francois Davodeau, Michel Cherel, Jacques Barbet
Cancer Research Department, Inserm, Universite de Nantes, U601, Nantes, France
Correspondence Address:
Jean-Francois Chatal
GIP Arronax, 1, rue Aronnax, Nantes-Saint-Herblain 44818
France
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0973-1482.55139
|
|
|
Radioimmunotherapy (RIT) has been proven effective in the treatment of radiosensitive non-Hodgkin lymphoma but, for radioresistant solid tumors, new approaches are necessary to improve the clinical effectiveness. A real improvement has been the introduction of the pretargeting technology which appeared to be able to significantly increase tumor-to-normal organ uptake ratios.Another very promising approach consists in associating RIT with other treatment modalities. Finally the use of alpha particle-emitting radionuclides such as astatin-211 or bismuth-213 (alpha-RIT) should allow to efficiently eradicate disseminated microscopic clusters of tumor cells or isolated tumor cells which fit well with the short path length of alpha particles. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
